RxDoctor Payments Data

Ryan Hall, MD

Internal Medicine · Fairmont, WVNPI 1184944241

Payments from drug & device makers

$292in general payments, 2019–2025

Across 14 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$58
  • Abbott$44
  • Pfizer$38
  • GSK$38
  • AbbVie$37
  • Boehringer Ingelheim$31
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$292100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$58
Abbott2$44
Pfizer2$38
GSK2$38
AbbVie2$37
Boehringer Ingelheim1$31
Novartis1$28
Lilly USA, LLC1$18

How this compares

$292 in reported general payments places this provider in the 55th percentile of 573 internal medicine providers in West Virginia.

See all internal medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$6,692
Medicare patients
208
Services billed
375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$132,353
JanuviaSitagliptin Phosphate58$64,292
EliquisApixaban51$50,800
MounjaroTirzepatide29$28,542
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$22,799
XareltoRivaroxaban22$21,788
ArexvyRsvpref3 Antigen/As01e/Pf75$19,653
Spiriva HandihalerTiotropium Bromide23$15,793
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog45$14,621
TradjentaLinagliptin13$11,513
Breo ElliptaFluticasone/Vilanterol24$9,708
Tresiba Flextouch U-200Insulin Degludec17$8,119
Incruse ElliptaUmeclidinium Bromide20$7,334
Albuterol Sulfate HfaAlbuterol Sulfate159$6,752
Combivent RespimatIpratropium/Albuterol Sulfate12$5,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$58$132,353130 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Incruse Ellipta, Shingrix$38$63,573168 claims
PfizerEliquis$38$50,80051 claims
Lilly USA, LLCMounjaro$18$28,54229 claims
Boehringer IngelheimTradjenta, Combivent Respimat$31$17,15625 claims
AbbVieSavella$37$5,62112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 573 internal medicine providers in West Virginia.

Other internal medicine in Fairmont

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →